Company Profile

FesariusTherapeutics Inc (AKA: Fesarius Therapeutics Inc)
Profile last edited on: 9/21/22      CAGE: 7EV34      UEI: YTNJCJM8KS58

Business Identifier: Engineered skin replacement
Year Founded
2015
First Award
2019
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

760 Parkside Avenue
Brooklyn, NY 11226
   (917) 589-4850
   N/A
   www.fesariustherapeutics.com
Location: Single
Congr. District: 09
County: New York

Public Profile

Anchored in work originally initiated and undertaken at Cornell (Bioregenerative Medicine and Surgery Lab) Fesarius Therapeutics, Inc. is an early stage biomedical company structured around development of an engineered skin replacement product using patented microsphere hydrogel technology. With the effort being to deliver superior healing outcomes for complex wounds, Fesarius Therapeutics' foundational scaffold technology - also licensed from Cornell University - offers the added advantage of improving patient lives and likely lowering the cost of related medical care. The expectation is that the firm's objective to have usable caability could be acheived in about five years.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,358,238
Project Title: Dermisphere™: an Advanced Dermal Regeneration Scaffold for Reconstructive Surgery
0 1 NIH $883,910
Project Title: An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery

Key People / Management

  Brett Spector -- Co-Founder & CEO

  Rachael Cohen -- Biomedical Engineer

  Gabor Forgacs -- Director

  Jarren Frame -- Director of Business Development

  Maria Lapshina -- Research Scientist

  Yulia Sapir Lekhovitser -- Chief Scientific Officer

  Yulia Sapir-Lekhovitser -- Chief Science Officer

  Jason Spector -- Co-Founder & Scientific Advisor

  Adam Weisel -- Senior Research Scientist

Company News

There are no news available.